Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) and Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Eupraxia Pharmaceuticals and Cartesian Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Eupraxia Pharmaceuticals | 1 | 1 | 4 | 2 | 2.88 |
| Cartesian Therapeutics | 1 | 0 | 5 | 0 | 2.67 |
Eupraxia Pharmaceuticals presently has a consensus target price of $15.00, indicating a potential upside of 124.22%. Cartesian Therapeutics has a consensus target price of $33.00, indicating a potential upside of 378.96%. Given Cartesian Therapeutics’ higher probable upside, analysts clearly believe Cartesian Therapeutics is more favorable than Eupraxia Pharmaceuticals.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Eupraxia Pharmaceuticals | N/A | N/A | -$38.58 million | ($1.05) | -6.37 |
| Cartesian Therapeutics | $2.80 million | 72.30 | -$130.30 million | ($5.90) | -1.17 |
Eupraxia Pharmaceuticals has higher earnings, but lower revenue than Cartesian Therapeutics. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
87.0% of Cartesian Therapeutics shares are owned by institutional investors. 37.2% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Eupraxia Pharmaceuticals and Cartesian Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Eupraxia Pharmaceuticals | N/A | -87.56% | -51.20% |
| Cartesian Therapeutics | -8,550.65% | N/A | -28.25% |
Volatility & Risk
Eupraxia Pharmaceuticals has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500.
Summary
Cartesian Therapeutics beats Eupraxia Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.
About Cartesian Therapeutics
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
